FR2903311B1 - Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoietiques contre la toxicite hematologique des agents chimiotherapeutiques - Google Patents

Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoietiques contre la toxicite hematologique des agents chimiotherapeutiques

Info

Publication number
FR2903311B1
FR2903311B1 FR0606253A FR0606253A FR2903311B1 FR 2903311 B1 FR2903311 B1 FR 2903311B1 FR 0606253 A FR0606253 A FR 0606253A FR 0606253 A FR0606253 A FR 0606253A FR 2903311 B1 FR2903311 B1 FR 2903311B1
Authority
FR
France
Prior art keywords
histamine
chemotherapeutic agents
receptor ligands
hematopoietic progenitors
hematological toxicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0606253A
Other languages
English (en)
Other versions
FR2903311A1 (fr
Inventor
Elke Schneider
Michel Dy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Paris 5 Rene Descartes
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Paris 5 Rene Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Paris 5 Rene Descartes filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR0606253A priority Critical patent/FR2903311B1/fr
Priority to PCT/FR2007/001181 priority patent/WO2008006974A2/fr
Publication of FR2903311A1 publication Critical patent/FR2903311A1/fr
Application granted granted Critical
Publication of FR2903311B1 publication Critical patent/FR2903311B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0606253A 2006-07-10 2006-07-10 Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoietiques contre la toxicite hematologique des agents chimiotherapeutiques Expired - Fee Related FR2903311B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR0606253A FR2903311B1 (fr) 2006-07-10 2006-07-10 Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoietiques contre la toxicite hematologique des agents chimiotherapeutiques
PCT/FR2007/001181 WO2008006974A2 (fr) 2006-07-10 2007-07-10 Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoïetiques contre la toxicite hematologique des agents chimiotherapeutiques.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0606253A FR2903311B1 (fr) 2006-07-10 2006-07-10 Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoietiques contre la toxicite hematologique des agents chimiotherapeutiques

Publications (2)

Publication Number Publication Date
FR2903311A1 FR2903311A1 (fr) 2008-01-11
FR2903311B1 true FR2903311B1 (fr) 2012-06-15

Family

ID=37680534

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0606253A Expired - Fee Related FR2903311B1 (fr) 2006-07-10 2006-07-10 Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoietiques contre la toxicite hematologique des agents chimiotherapeutiques

Country Status (2)

Country Link
FR (1) FR2903311B1 (fr)
WO (1) WO2008006974A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150148538A1 (en) * 2013-11-27 2015-05-28 Gaetan Terrasse Use of an h4 agonist molecule to treat acute leukemia
FR3013595B1 (fr) * 2013-11-27 2017-09-01 Gaetan Terrasse Utilisation d'une molecule h4 agoniste pour le traitement des leucemie aigues
FR3048883B1 (fr) 2016-03-18 2020-10-02 Gaetan Terrasse Utilisation d'une molecule h4 agoniste pour le traitement de la fibrose pulmonaire idiopathique
EP4291073A1 (fr) 2021-12-21 2023-12-20 The Ergo Baby Carrier, Inc. Siège sauteur réglable

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028013A1 (fr) * 1993-05-20 1994-12-08 Research Corporation Technologies, Inc. Peptides de suppression de la proliferation de cellules souches myeloides et de traitement du choc septique
CA2341742A1 (fr) * 1998-08-24 2000-03-02 Maxim Pharmaceuticals, Inc. Activation et protection de cellules t (cd4+ et cd8+) a l'aide d'un agoniste du recepteur h2 et d'autres agents activant les cellules t
US6375944B1 (en) * 1998-09-25 2002-04-23 The Wistar Institute Of Anatomy And Biology Methods and compositions for enhancing the immunostimulatory effect of interleukin-12
US20040127395A1 (en) * 2002-09-06 2004-07-01 Desai Pragnya J. Use of histamine H4 receptor modulators for the treatment of allergy and asthma
WO2005044807A2 (fr) * 2003-09-30 2005-05-19 Janssen Pharmaceutica N.V. Composes de benzoimidazole
US20060079510A1 (en) * 2004-09-30 2006-04-13 Kristoffer Hellstrand Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis

Also Published As

Publication number Publication date
WO2008006974A3 (fr) 2008-05-22
WO2008006974A2 (fr) 2008-01-17
FR2903311A1 (fr) 2008-01-11

Similar Documents

Publication Publication Date Title
ATE527262T1 (de) Neue tomaymycin derivate enhaltende zytotoxische mittel
EP2018863A4 (fr) Composé hétérocyclique fusionné et utilisation
SE0600038L (sv) Svarvskär och svarvverktyg
FR2902998B1 (fr) Utilisation d'au moins un derive c-glycoside a titre d'agent apaisant
IL195492A0 (en) Phenyl-pyrazole derivatives as non-steroidal glucocoricoid receptor ligands
ZA200901320B (en) Sulfonamide derivatives as adrenerigic agonists and muscarinic antgonists
FR2899087B1 (fr) Protection pour endoscope et endoscope correspondant
RS56044B1 (sr) Primena kombinovanih preparata koji sadrže antimikotike
EP1855669A4 (fr) Compositions liposomales pour administration parenterale d'agents
GB0821019D0 (en) Nanostructures suitable for delivery of agents
FR2903311B1 (fr) Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoietiques contre la toxicite hematologique des agents chimiotherapeutiques
FR2905447B1 (fr) Chapeau de protection pour recipient de fluide
FR2918279B1 (fr) Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
FR2901816B1 (fr) Structure d'enveloppe de protection pour un pilon
EP2120548A4 (fr) Milieu hydrosoluble contenant des agents anti-microbiens
EP2027249A4 (fr) Détection de plusieurs types de leucocytes
FR2906740B1 (fr) Machine pour verre de lunettes
EP1877043A4 (fr) Utilisation de paeonol dans l'inhibition de l'angiogenese ou dans l'amelioration de la radiosensibilisation
FR2907109B1 (fr) Indicateur de position de fleche pour grue
FR2941864B1 (fr) Substance active pour la protection de fgf-2
FR2906173B1 (fr) Dispositif pour l'usinage en plafond de pieces fixes
EP1985294A4 (fr) Agent d'amelioration de fonction hepatique
FR2891810B1 (fr) Structure de protection pour container
FR2900954B1 (fr) Anti vol pour casque integral pour cycles moto cycles et assimiles
FR2908037B1 (fr) Ensemble de protection pour seringue

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

ST Notification of lapse

Effective date: 20230305